TATE and KN046 in MCRC
Stopped Business Operation Strategy Adjustment
Conditions
- Colorectal Cancer with Hepatic Metastases
Interventions
- DRUG: KN046 （PD-L1/CTLA4 BsAb）
- PROCEDURE: TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization
Sponsor
Zhejiang Raygene Pharmaceuticals Co., Ltd
Collaborators